Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.
1. A method for treating a patient suffering from a lymphoma, wherein said method comprises the steps of: i) measuring in a tumor sample obtained from the patient, prior to anti-cancer treatment, the gene expression level of at least all of the following genes: CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21; ii) comparing every expression level determined at step i) with a corresponding predetermined reference value; iii) selecting the patient as being a responder to at least one immunotherapy when all expression levels determined at step i) are either higher or lower than the corresponding predetermined reference value; and iv) administering said immunotherapy to said patient assessed as being a responder thereto in step iii), wherein said at least one immunotherapy is an antibody directed against any one of CTLA4, PD1, PDL1, TIM3, LAG3, B7H3, B7H4, TREM, BTLA, LIGHT or B7H6; or an immune cell selected from T cells, NK cells, dendritic cells or B cells; or any combination thereof.
2. The method according to claim 1 , wherein the lymphoma is Hodgkin's disease or a non-Hodgkin's lymphoma.